ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

1L Therapy in CLL: What Are the Best Options?

SOHO Brazil 2024

J. Burger

Clinical Practice Updates in CLL/SLL

Integrity CE

M. Cortese, D. Wallace, A. Niu

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

FL: How Do I Deal With Relapse?

SOHO Brazil 2024

B. Kahl

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Summary of Bispecific Antibodies for Follicular Lymphoma

UChicago Medicine

D. Russler-Germain

ASCO® 2023 Summary: "Experts Discuss Key Abstracts in CLL"

Insights from 2023 ASCO® Annual Meeting

S. O'Brien, C. Coombs

3L in CLL: The Best Options in a Patient Double-Refractory to Covale…

SOHO Brazil 2024

J. Burger

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Frontline CLL Learnings From Phase 3 RESONATE-2, iLLUMINATE, and E19…

Cleveland Clinic Taussig Cancer Institute

A. Winter

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

Follicular Lymphoma Management: What Is the New Order?

SOHO 2023 Eleventh Annual Meeting

B. Kahl

CLL Treatment Sequencing: The Importance of First Choice

City of Hope

S. Rosen

ESMO 2024 Summary: Updates in the Treatment of MCL

2024 ESMO Annual Meeting Insights Hub

G. Hess

Sequencing of Bispecifics With Other Therapies in DLBCL

UChicago Medicine

E. Budde

FDA Approval of Zanubrutinib in R/R FL: What You Need to Know

Christopher Flowers

Summary of Recent Advances in Follicular Lymphoma

Louisville Hematology Highlights

S. Gaballa

EZH2 Inhibition in FL: Overview and Analysis of the SYMPHONY-1 Trial

Northwestern Medicine Oncology and Hematology

L. Gordon

Sequencing Therapies in CLL: The Importance of First-Line Treatment …

Nicole Lamanna